Last reviewed · How we verify
Phase 2 Double-blind, Randomized, Placebo-controlled, Parallel Group, Multi-center Study
A topical treatment applied twice daily for 4 weeks to induce disappearance of facial actinic keratosis (AK). First 4 weeks treatment (visit 1, 2 and 3 at 0,2 an 4 weeks) treated as a double blind parallel study. From weeks 4 to 7 (visit 3 to visit 4) all patients to be treated by the active component.
Details
| Lead sponsor | Assuta Hospital Systems |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 52 |
| Start date | 2013-07 |
| Completion | 2014-07 |
Conditions
- Actinic Keratosis of Face and Scalp
Interventions
- AD17137 topical treatment
- Placebo
Primary outcomes
- Complete Clearance (100% of AK lesions) from baseline (Visit 1) to Visits 3 and 4. Complete Clearance (100% of AK lesions) from baseline (Visit 1) to Visits 3 and 4. — baseline to Week 7
Countries
Israel